In vitro screening of drug metabolism during drug development: Can we trust the predictions?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 1, Issue 1, 2005, Pages 49-59

  Pelkonen, Olavi ^a   Raunio, Hannu ^b  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

CYP; cytochrome P450; drug metabolism

Indexed keywords

DRUG;

ANIMAL; CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; DRUG SCREENING; HUMAN; IN VITRO STUDY; METABOLISM; PREDICTION AND FORECASTING; REVIEW; STANDARD;

ANIMALS; COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS;

EID: 33644858668     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.1.1.49     Document Type: Review

References (44)

1. LIN JH, LU AYH: Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. (1997) 49:403-449. (Pubitemid 28030947)
2. VAN DE WATERBEEMD H, GIFFORD E: ADMET in silico modelling: towards prediction paradise? Nature Rev. Drug Dev. (2003) 2:192-203.
3. BAILLIE TA, CAYEN MN, FOUDA H et al.: Contemporary issues in toxicology. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. (2002) 182:188-196.
4. UETRECHT J: Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. DDT (2003) 8:832-837. (Pubitemid 37083340)
5. GUENGERICH FP, RENDIC S: Human cytochrome P450 enzymes (human CYPs): human cytochrome P450 enzymes, a status report summarizing their reactions, substrates, inducers, and inhibitors -1st update. Drug Metab. Rev. (2002) 34:1-450.
6. BRANDON EF, RAAP CD, MEIJERMAN I, BEIJNEN JH, SCHELLENS JH: An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacol. (2003) 189:233-246. (Pubitemid 36677534)
7. PLANT N: Strategies for using in vitro screens in drug metabolism. DDT (2004) 9:328-336. (Pubitemid 38373652)
8. ANDERSSON TB, SJÖBERG H, HOFFMANN K-J et al.: An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab. Disp. (2001) 29:712-720. (Pubitemid 32374573)
9. SALONEN JS, NYMAN L, BOOBIS AR, EDWARDS RJ et al.: Comparative studies on the CYP-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab. Disp. (2003) 31:1093-1102. (Pubitemid 37048280)
10. PELKONEN O, MYLLYNEN P, TAAVITSAINEN P et al.: Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica (2001) 31:321-343. (Pubitemid 32679311)
11. TUCKER GT, HOUSTON JB, HUANG S-M: EUFEPS Conference Report. Optimising drug development: strategies to assess drug metabolism/ transporter interaction potential - towards a consensus. Eur. J. Pharm. Sci. (2001) 13:417-428. (Pubitemid 32611600)
12. YUAN R, MADANI S, WEI X-X, REYNOLDS K, HUANG S-M: Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Disp. (2002) 30:1311-1319. (Pubitemid 35397032)
13. WALSKY RL, OBACH RS: Validated assays for human cytochrome P450 activities. Drug Metab. Disp. (2004) 32:647-660. (Pubitemid 38668158)
14. STREETMAN DS, BERTINO JS Jr, NAFZIGER AN: Phenotyping of drugmetabolizing enzymes in adults: a review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics (2000) 10:187-216. (Pubitemid 30242736)
15. CLARKE SE, JEFFREY P: Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica (2001) 31:591-598. (Pubitemid 32826393)
16. OBACH RS, BAXTER JG, LISTON TE et al.: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. (1997) 283:46-58. (Pubitemid 27438945)
17. ITO K, IWATSUBO T, KANAMITSU S, NAKAJIMA Y, SUGIYAMA Y : Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Ann. Rev. Pharmacol. Toxicol. (1998) 38:461-499. (Pubitemid 28231503)
18. HOUSTON JB, GALETIN A: Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab. Rev. (2003) 35:393-415. (Pubitemid 38018114)
19. KOSTIAINEN R, KOTIAHO T, KUURANNE T, AURIOLA S: Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J. Mass Spectrom. (2003) 38:357-372. (Pubitemid 36582213)
20. LEE MS, KERNS EH: LC/MS applications in drug development. Mass Spectrom. Rev. (1999) 18:187-279. (Pubitemid 129660662)
21. NASSAR A-EF, TALAAT RE: Strategies for dealing with metabolite elucidation in drug discovery and development. DDT (2004) 9:317-327. (Pubitemid 38373651)
22. WILLIAMS DP, PARK BK: Idiosyncratic toxicity: the role of toxicophores and bioactivation. DDT (2003) 8:1044-1050. (Pubitemid 38018811)
23. GALETIN A, BROWN C, HALIFAX D, ITO K, HOUSTON JB: Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab. Disp. (2004) 32:1411-1420. (Pubitemid 39564561)
24. BJORNSSON TD, CALLAGHAN JT, EINOLF HJ et al.: The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Disp. (2003) 31:815-832. (Pubitemid 36759050)
25. KREMERS P: In vitro tests for predicting drug-drug interactions: the need for validated procedures. Pharmacol. Toxicol. (2002) 91:209-217. (Pubitemid 35370429)
26. ITO K, BROWN HS, HOUSTON JB: Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br. J. Clin. Pharmacol. (2004) 57:473-486. (Pubitemid 38519653)
27. HONKAKOSKI P, NEGISHI M: Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem. J. (2000) 347:321-337. (Pubitemid 30229378)
28. HONKAKOSKI P: Nuclear receptors CAR and PXR in metabolism and elimination of drugs. Curr. Pharmacogenomics (2003) 1:75-85.
29. A modular approach to the ECVAM principles on test validity. Altern. Lab. Anim. (2004) 32:467-472.
30. JOHNSON EF: Deciphering substrate recognition by drug-metabolizing cytochromes P450. Drug Metab. Disp. (2003) 31:1532-1540.
31. KEMP CA, MARECHAL JD, SUTCLIFFE MJ: Progress in cytochrome P450 active site modelling. Arch. Biochem. Biophys. (2005) 433:361-368. (Pubitemid 39592790)
32. KEMP CA, FLANAGAN JU, VAN ELDIK AJ et al.: Validation of model cytochrome P450 2D6: an in silico toll for predicting metabolism and inhibition. J. Med. Chem. (2004) 47:5340-5346. (Pubitemid 39382784)
33. LEWIS DF, MODI S, DICKINS M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab. Rev. (2002) 34:69-82. (Pubitemid 34311089)
34. LEWIS DF, JABOBS MN, DICKINS M: Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov. Today (2004) 9:530-537. (Pubitemid 38739334)
35. EKINS S, DE GROOT MJ, JONES JP: Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab. Disp. (2001) 29:936-944. (Pubitemid 32605906)
36. EKINS S, BERBAUM J, HARRISON RK: Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab. Disp. (2003) 31:1077-1080. (Pubitemid 37048276)
37. RAHNASTO M, RAUNIO H, POSO A, WITTEKINDT C, JUVONEN RO: Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolising CYP2A6 enzyme. J. Med. Chem. (2005) 48:440-449. (Pubitemid 40139786)
38. ERHARDT PW: A human drug metabolism database: potential roles in the quantitative predictions of drug metabolism and metabolism-related drug-drug interactions. Curr. Drug Metab. (2003) 4:411-422. (Pubitemid 37287555)
39. PELKONEN O, BAUMANN A, REICHEL A: Pharmacokinetic challenges in drug discovery. Ernst Schering Research Foundation Workshop 37. Springer, Berlin, Germany (2002).
40. THOMPSON TN: Early ADME in support of drug discovery: the role of metabolic stability studies. Curr. Drug Metab. (2000) 1:215-241.
41. GEBHARDT R, HENGSTLER JG, MULLER D et al.: New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev. (2003) 35:145-213. (Pubitemid 37048295)
42. MASIMIREMBWA CM, BREDBERG U, ANDERSSON TB: Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin. Pharmacokinet. (2003) 42:515-528. (Pubitemid 36801870)
43. ANSEDE JH, THAKKER DR: Highthroughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J. Pharm. Sci. (2004) 93:239-255. (Pubitemid 38174247)
44. GOMEZ-LECHON MJ, DONATO MT, CASTELL JV, JOVER R: Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr. Drug Metab. (2004) 5:443-462. (Pubitemid 39276606)